Amgen continues to rule the Top 10 Biopharma rankings, but 2005 saw a couple of players make great strides. Genentech and Gilead continued to post huge gains (+46% each) on the strength of their oncology and HIV drugs, respectively. Read More »
THIS PROFILE IS FROM 2006, AND CONTAINS INFORMATION THAT MAY NO LONGER BE CURRENT.
1 Medimmune Way
Gaithersburg, MD 20878
Tel: (877) 633-4411
Fax: (301) 398-9000
2,215… Read More »
PDL BioPharma, Inc. plans to move its corporate headquarters from Fremont to Redwood City, CA during the third quarter of 2007. PDL has signed long-term leases for two existing buildings that total approximately 450,000 sq.-ft. The new headquarters w… Read More »
Array BioPharma, Inc. achieved a research milestone in its collaboration with Genentech, Inc. The two companies initiated an oncology collaboration in January 2004 to identify small molecule development compounds against multiple targets. The milesto… Read More »
Sentry Logistic Solutions launched its services and the opening of its $8 million, 53,000-sq.-ft. facility designed for cold chain logistics, storage and packing of bulk pharmaceutical and biotechnology components and finished products.
"Se… Read More »
Array BioPharma and AstraZeneca have selected a third compound for their small molecule MEK anti-cancer program, triggering a $1 million milestone payment by AstraZeneca. The second compound was selected in January 2006, also triggering a $1 million… Read More »
PDL BioPharma, Inc. has named Andrew Guggenhime senior vice president and chief financial officer. Mr. Guggenhime will join the company's senior management team reporting directly to chief executive officer Mark McDade, and will be responsible for al… Read More »
Cardinal Health has entered a feasibility and commercial option agreement with Centocor, Inc. to develop cell lines using Cardinal's Gene Product Expression (GPEx) cell line engineering technology. Cardinal Health will use its GPEx technology to engi… Read More »
Wyeth Pharmaceuticals and Trubion Pharmaceuticals, Inc. have formed a strategic alliance for the discovery, development and commercialization of novel biopharmaceutical products to treat inflammatory disease and cancer. The alliance will utilize Trub… Read More »
The Top 10 Biopharma rankings saw two more companies reach the billion-dollar mark in revenues in 2004, as Gilead and MedImmune crossed that threshold. Unfortunately, a bad case of the flu sent Chiron back under the billion-dollar mark, as its fluvirin vaccine revenues dropped from $219 million in 2003 to a mere $2 million last year, after its well-documented manufacturing problems. Read More »